IP Library › Granted Patent US 6,846,806
Granted Patent B2
US 6,846,806 · App. 10/039,317 · Granted Jan 25, 2005

Peptide inhibitors of Hepatitis C virus NS3 protein

Assignee: Bristol-Myers Squibb Company
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,846,806
App. No.
10/039,317
Granted
Jan 25, 2005
Kind
B2
Abstract

This invention relates to a novel class of peptides having the Formula (I): which are useful as serine protease inhibitors, and more particularly as Hepatitis C virus(HCV) NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same in the treatment of HCV infection.

Claims (1)

1. The compound (2-pyrazinecarbonyl)-Val-Val-Hyp(OBn)-(1R)-1-amino-3-(4-trifluoromethyl)phenylpropylboronic acid (+)-pinanediol ester, and pharmaceutically acceptable salts and solvates thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2002
From: PRIESTLEY, E. SCOTT
To: BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY)
Reel/Frame 012869/0325 →
Continuity (2)
Provisional Application 6024255700 · Oct 23, 2000
Related Publication 20020177725A1 · Nov 28, 2002